Gambogic acid suppresses nasopharyngeal carcinoma via rewiring molecular network of cancer malignancy and immunosurveillance.
Cancer repression
Chemotherapy
Gambogic acid
Immunotherapy
Nasopharyngeal carcinoma
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
11
03
2022
revised:
16
04
2022
accepted:
19
04
2022
entrez:
5
6
2022
pubmed:
6
6
2022
medline:
9
6
2022
Statut:
ppublish
Résumé
Nasopharyngeal carcinoma (NPC) is a malignant tumor highly prevalent in Southeast Asia. The distant metastasis and disease recurrence are still unsolved clinical problems. In recent years, traditional Chinese medicine (TCM) monomers have become significantly attractive due to their advantages. Using high throughput drug sensitivity screening, we identified gambogic acid (GA) as a common TCM monomer displaying multiple anti-NPC effects. GA could effectively inhibit the proliferation of low differentiated cells and highly metastatic cells in NPC via inducing apoptosis and G2/M cell cycle arrest. In addition, GA obviously repressed the abilities of cell clone, migration, invasion, angiogenesis and represented satisfied synergistic effects combined with chemotherapy. Importantly, we found the elevated immune checkpoint CD47 stimulated after chemotherapy was dramatically impaired by GA treatment. Mechanically, the network pharmacology analyses unraveled that the oncogenic signaling pathways including STATs were rewired by GA treatment. Taken together, our study reveals a molecular basis and provides a rationale for GA application as the treatment regime in NPC therapy in future.
Identifiants
pubmed: 35658246
pii: S0753-3322(22)00401-2
doi: 10.1016/j.biopha.2022.113012
pii:
doi:
Substances chimiques
Xanthones
0
gambogic acid
8N585K83U2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113012Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.